Navigation Links
Ocera Therapeutics Closes $35.5 Million Series C Financing
Date:2/20/2008

- Funds will support Phase 3 Trials for Crohn's Disease, Pouchitis and

Other Pipeline Products -

SAN DIEGO, Feb. 20 /PRNewswire/ -- Ocera Therapeutics, a biopharmaceutical company focused on the licensing, development and commercialization of proprietary compounds to treat a broad range of gastrointestinal and liver diseases, has announced the completion of a $35.5 million Series C financing from a syndicate of highly-regarded investors.

New investor Montagu Newhall Associates is leading the round and is joined by InterWest Partners; AgeChem Venture Fund; Cross Creek Capital, an affiliate of Wasatch Advisors; FinTech and CDIB BioScience. Previous investors, Domain Associates, Sofinnova Ventures, and Thomas, McNerney & Partners, also participated in the round. To date, Ocera has raised a total of $62 million. In conjunction with the financing, Linda Grais of InterWest Partners will take a seat on the Ocera Board of Directors representing Montagu Newhall Associates and the Series C investors.

"I am extremely pleased with the investor confidence we've seen from this oversubscribed financing round," commented Laurent Fischer, M.D., co-founder, president and CEO of Ocera Therapeutics. "We are privileged to have attracted a syndicate of renowned investors with specific expertise in the gastrointestinal market as well as international and crossover investors and we welcome Linda Grais' guidance as she joins our board of directors."

Linda Grais M.D., J.D., is a partner with InterWest Partners and brings a wide array of experience to the team. Prior to InterWest, Dr. Grais served as founder and executive vice president of SGX Pharmaceuticals and was an attorney at Wilson Sonsini Goodrich & Rosati. Before practicing law, Dr. Grais worked as an assistant clinical professor of Internal Medicine and Critical Care at the University of California, San Francisco. She also served as a consultant to the Institute of Medicine and is a member of the Stanford Law School Board of Visitors.

"Ocera Therapeutics is a unique biopharmaceutical company which has achieved bringing AST-120 through Phase 3 trials for Crohn's disease in a very short time and in a capital efficient manner," commented Ashton Newhall, general partner, Montagu Newhall Associates. "Our confidence in the ability of Ocera's management team to deliver on its goals and expand the market opportunity for this product by focusing on orphan drug as well as other indications with unmet medical needs makes this an exciting opportunity. We look forward to upcoming milestones related to AST-120."

About AST-120

AST-120 Spherical Adsorbent Carbon is not absorbed in the body. It was in-licensed in 2005 from Kureha of Japan. Ocera has completed enrollment in FHAST1, the Fistula Healing with AST-120 Phase 3 pivotal trial in Fistulizing Crohn's disease conducted in North America, Europe and Israel. Ocera is studying AST-120 in a Phase 2 trial for Pouchitis, an orphan drug indication, and has also initiated proof-of-concept trials in Irritable Bowel Syndrome, Hepatic Encephalopathy and PPI-resistant GERD.

About Ocera Therapeutics

Ocera Therapeutics, Inc. is a privately held biopharmaceutical company focused on the licensing, development and commercialization of proprietary compounds to treat a broad range of gastrointestinal and liver diseases. Based in San Diego, Ocera was co-founded by Dr. Eckard Weber of Domain Associates and Dr. Laurent Fischer. The Company is pursuing the development of AST-120, a "pipeline-in-a-drug" for Inflammatory Bowel Diseases, such as Crohn's and Pouchitis and exploring its potential to treat other gastro-intestinal and liver diseases. Ocera Therapeutics has raised $62 million dollars in venture financing from Montagu Newhall Associates; InterWest Partners; AgeChem Venture Fund; Cross Creek Capital, an affiliate of Wasatch Advisors; FinTech; CDIB BioScience; Domain Associates; Sofinnova Ventures and Thomas, McNerney & Partners. Additional information on the Company can be found at http://www.oceratherapeutics.com.


'/>"/>
SOURCE Ocera Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Ocera Therapeutics Announces Positive Results with AST-120 in Pouchitis
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
3. United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results
4. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
5. Cell Therapeutics, Inc. (CTI) Announces Cancellation of Approximately $9.1 Million of Existing Notes due 2008
6. PeriCor Therapeutics Appoints K. Tucker Andersen to Board of Directors
7. United Therapeutics to Announce Fourth Quarter and Annual 2007 Financial Results Before Market Open on Tuesday, February 19, 2008
8. Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
9. Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
10. Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008
11. Logical Therapeutics Co-Founder and CEO Honored with a Distinguished Investigator Award from the American College of Critical Care Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Regular discussions on a ... take place between the two entities said Poloz. ... Ottawa , he pointed to the country,s ... the federal government. ... said, "Both institutions have common economic goals, why not sit ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in ... peritoneal or pleural mesothelioma. Their findings are the subject of a new article on ... biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients that ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016   ... management and verification solutions, has partnered with ... software solutions for Visitor Management, Self-Service Kiosks ... provides products that add functional enhancements to ... provides corporations and venues with an automated ...
(Date:6/15/2016)... 15, 2016 Transparency Market ... Recognition Market by Application Market - Global Industry Analysis Size ... to the report, the  global gesture recognition market ... and is estimated to grow at a CAGR ... 2024.  Increasing application of gesture recognition ...
(Date:6/2/2016)... 2016 The Department of Transport Management ... 44 million US Dollar project, for the , ... Personalization, Enrolment, and IT Infrastructure , to ... and implementation of Identity Management Solutions. Numerous renowned international vendors ... Decatur was selected for the most compliant and ...
Breaking Biology News(10 mins):